What are the side effects of rasburicase?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Rasburicase can cause several side effects, including severe allergic reactions, hemolytic anemia, and methemoglobinemia, particularly in patients with G6PD deficiency, as reported in the study by 1. The most common side effects of rasburicase include:

  • Nausea
  • Vomiting
  • Fever
  • Headache
  • Abdominal pain
  • Constipation
  • Diarrhea More serious side effects that require immediate medical attention include:
  • Severe allergic reactions (anaphylaxis)
  • Hemolytic anemia
  • Methemoglobinemia Rasburicase works by converting uric acid to allantoin, which is more soluble and easily excreted by the kidneys, making it effective for treating or preventing tumor lysis syndrome, as described in the study by 1. However, this rapid breakdown of uric acid can sometimes cause kidney problems, especially if adequate hydration is not maintained during treatment. Patients should be monitored for signs of kidney dysfunction, electrolyte abnormalities, and blood disorders during treatment with rasburicase, as recommended in the guidelines by 1. It is also important to note that rasburicase is contraindicated in patients with a known G6PD deficiency, and G6PD testing is recommended before administration, as stated in the study by 1. Additionally, patients may develop antibodies against rasburicase, potentially reducing its effectiveness with repeated use, as reported in the study by 1. Overall, the use of rasburicase should be carefully considered and monitored to minimize the risk of side effects and ensure effective treatment, as recommended in the guidelines by 1.

From the FDA Drug Label

Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase. (6.1) The side effects of rasburicase include:

  • Vomiting
  • Nausea
  • Fever
  • Peripheral edema
  • Anxiety
  • Headache
  • Abdominal pain
  • Constipation
  • Diarrhea
  • Hypophosphatemia
  • Pharyngolaryngeal pain
  • Increased alanine aminotransferase 2

From the Research

Side Effects of Rasburicase

The side effects of rasburicase include:

  • Haematological adverse events 3
  • Hypersensitivity reactions 3
  • Methemoglobinemia, which is a serious rare adverse effect, more common in patients with G6PD deficiency 4, 5, 6
  • Hemolytic anemia, which can occur in patients with G6PD deficiency 4, 7, 6
  • Cyanosis, pallor, and oxygen saturation gap, which are clinical presentations of methemoglobinemia 4
  • Acute renal failure and ARDS, which can be complications of rasburicase-induced hemolysis and methemoglobinemia 6

Patients at Risk

Patients at risk of developing side effects from rasburicase include:

  • Those with G6PD deficiency, who are at high risk of methemoglobinemia and hemolytic anemia 4, 7, 6
  • Those with a history of haemolysis or methaemoglobinaemia 3
  • Those with glucose-6-phosphate dehydrogenase deficiency, who are contraindicated for rasburicase treatment 3

Management of Side Effects

Management of side effects includes:

  • Prompt diagnosis and appropriate management of methemoglobinemia and hemolytic anemia 4, 5, 6
  • Oxygen supplementation, ascorbic acid, and blood transfusion for treatment of methemoglobinemia 4, 6
  • Avoidance of methylene blue in patients with G6PD deficiency, as it can worsen methemoglobinemia 4, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Rasburicase-induced methemoglobinemia: The eyes do not see what the mind does not know.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018

Research

Rasburicase-induced Hemolytic Anemia in an Adolescent With Unknown Glucose-6-Phosphate Dehydrogenase Deficiency.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.